July 25, 2026Open Access
View Full PaperTranscatheter aortic valve implantation 10-year anniversary: review of current evidence and clinical implications
Key Result
Transcatheter aortic valve implantation (TAVI) has become the new standard of care for inoperable patients with symptomatic aortic stenosis and an alternative for selected high-risk operable patients.
Key Points
- This review aims to summarize the current evidence and implications surrounding transcatheter aortic valve implantation after 10 years of clinical use.
- Review of literature on transcatheter aortic valve implantation and its outcomes
- Analysis of randomized trials comparing TAVI to surgical aortic valve replacement
- Consideration of clinical experiences and implantations across multiple countries.
- Transcatheter aortic valve implantation has become the standard of care for inoperable patients with aortic stenosis.
- In selected high-risk patients, TAVI is considered a viable alternative to surgical aortic valve replacement.
- Over 50,000 TAVI procedures have been performed globally, indicating widespread acceptance and evolving technique.
Structured PICO
What is the current evidence and clinical implications of transcatheter aortic valve implantation (TAVI) compared to surgical aortic valve replacement (SAVR) in patients with severe symptomatic aortic stenosis?
P
Population
Patients with severe symptomatic aortic stenosis (AS), including those deemed 'inoperable' or at high risk but operable
I
Intervention
Transcatheter aortic valve implantation (TAVI)
C
Comparator
Surgical aortic valve replacement (SAVR)
This 10-year anniversary review summarizes the evolution of TAVI into the standard of care for inoperable patients and a viable alternative for high-risk operable patients with severe symptomatic aortic stenosis.
Abstract
Surgical aortic valve replacement (SAVR) is currently the standard of care to treat patients with severe symptomatic aortic stenosis (AS) and is generally accepted to alleviate symptoms and prolong survival. Based on the results of randomized trials, transcatheter aortic valve implantation (TAVI) is the new standard of care for patients with symptomatic AS who are deemed 'inoperable'. Debatably, TAVI is also an alternative to SAVR in selected patients who are at high risk but operable. As we approach 10 years of clinical experience with TAVI, with over 50 000 implantations in 40 countries, a review of the current literature and clinical outcomes with this rapidly evolving technology is appropriate.